Venture&Growth
Location
Heidelberg, Germany
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
mtm laboratories manufactures and commercializes in-vitro diagnostic tests for the analysis of cervical cancer. Worldwide, cervical cancer is the second most common cancer in women. mtm’s CINtec® technology detects a specific cellular biomarker (p16INK4a) and offers the potential for highly specific and accurate diagnosis of early-stage cervical cancer, even if it is without symptoms.
Since Gilde invested in mtm laboratories, the German company has clinically validated its diagnostic products and more than doubled its sales. mtm laboratories was acquired by Roche in 2011.
More mtm laboratories news
Study of CINtec® PLUS in the management of Pap negative but HPV positive women published
mtm laboratories Extends Series C Financing Round by EUR 7 Million ($9.7 Million)
MTM Laboratories – p16 Immuno-cytochemistry shows superior clinical performance to HPV testing
mtm’s CINtec® PLUS, delivers new solution to manage Pap negative but HPV positive women
mtm laboratories Announces the European Launch of CINtec(R) PLUS
MTM LABORATORIES – CINtec® p16 Histology test increases accuracy in diagnosing
GILDE HEALTHCARE II invests in mtm laboratories AG
Venture&Growth
Argá Medtech
Argá Medtech is developing the next generation non-thermal cardiac ablation system. The system for treating atrial fibrillation (AF) uses pulsed field ablation, the energy modality of choice because of a superior safety profile. Arga has a novel catheter design and unique
Venture&Growth
CatalYm
CatalYm is a clinical-stage immuno-oncology company improving the outcomes of existing checkpoint inhibitor therapies in difficult-to-treat cancer types. The company has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as a safe and efficacious immune
Venture&Growth
Tagworks
Tagworks Pharmaceuticals is a privately held therapeutics company based in the Netherlands. It leverages unique technologies to increase efficacy and decrease toxicity across multiple systemic treatment modalities. The company has pioneered a unique and proprietary Click-to-Release drug development technology, enabling
